Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $5.09 USD
Change Today -0.21 / -3.96%
Volume 634.2K
BCLI On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ CM
As of 8:10 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

brainstorm cell therapeutics (BCLI) Key Developments

BrainStorm Cell Therapeutics to Present Positive NurOwn® Phase 2a Clinical Data at American Academy of Neurology Annual Meeting

BrainStorm Cell Therapeutics Inc. announced that results from its phase 2a study of NurOwn® in amyotrophic lateral sclerosis (ALS) and additional analyses will be presented at the American Academy of Neurology annual meeting, taking place in Washington D.C. from April 18 to 25, 2015. NurOwn® is an autologous cell therapy in which bone marrow-derived mesenchymal stem cells are expanded and then, under proprietary conditions, induced to secrete several neurotrophic factors known to promote neuronal survival. BrainStorm has completed two clinical trials of these neurotrophic factor-secreting mesenchymal stem cells in Israel, and is currently enrolling a randomized, double-blind, placebo-controlled phase 2 study at three centers in the United States.

Brainstorm Cell Therapeutics Inc. Announces Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

Brainstorm Cell Therapeutics Inc. announced consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported operating loss of $2,666,000 against $1,382,000 a year ago. Pre-Tax Loss was $2,730,000 against $1,217,000 a year ago. Net loss was $2,730,000 or $0.18 per basic and diluted net loss per share from continuing operations compared to $1,217,000 or $0.10 per basic and diluted net loss per share from continuing operations a year ago. For the year, the company reported operating loss of $7,421,000 against $5,043,000 a year ago. Pre-Tax Loss was $9,246,000 against $4,899,000 a year ago. Net loss was $9,246,000 or $0.68 per basic and diluted net loss per share from continuing operations compared to $4,899,000 or $0.46 per basic and diluted net loss per share from continuing operations a year ago.

Brainstorm Cell Therapeutics Inc. Auditor Raises 'Going Concern' Doubt

Brainstorm Cell Therapeutics Inc. filed its 10-K on Mar 26, 2015 for the period ending Dec 31, 2014. In this report its auditor, Brightman Almagor Zohar & Co, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Brainstorm Cell Therapeutics Inc. to Report Q4, 2014 Results on Mar 26, 2015

Brainstorm Cell Therapeutics Inc. announced that they will report Q4, 2014 results at 9:00 AM, Eastern Standard Time on Mar 26, 2015

Brainstorm Cell Therapeutics Inc., Q4 2014 Earnings Call, Mar 26, 2015

Brainstorm Cell Therapeutics Inc., Q4 2014 Earnings Call, Mar 26, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BCLI:US $5.09 USD -0.21

BCLI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BCLI.
View Industry Companies
 

Industry Analysis

BCLI

Industry Average

Valuation BCLI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 11.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BRAINSTORM CELL THERAPEUTICS, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.